🟢 Viking Therapeutics is trading 12.49% up in after-hours trading after VK2735 advanced into Phase 3

Viking Therapeutics is trading at $33.69 (+12.49%) after reports that VK2735 advanced into Phase 3.

• It closed at $29.95, then surged in extended trading on September 15, 2026.
• VK2735 produced 14.7% weight loss over 13 weeks at the highest Phase 2 dose; two injectable Phase 3 trials are fully enrolled, with results expected in the second half of 2027.
• Broader risk-off conditions remain a countervailing backdrop.